BARI, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.254
EU - Europa 3.432
AS - Asia 1.211
SA - Sud America 20
AF - Africa 19
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 7
Totale 11.960
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.202
GB - Regno Unito 1.591
IT - Italia 548
CN - Cina 406
SE - Svezia 311
SG - Singapore 299
DE - Germania 291
HK - Hong Kong 221
FR - Francia 205
UA - Ucraina 159
TR - Turchia 134
FI - Finlandia 101
BG - Bulgaria 68
CA - Canada 38
ID - Indonesia 33
IN - India 31
BE - Belgio 28
LT - Lituania 25
IE - Irlanda 24
VN - Vietnam 22
RU - Federazione Russa 18
AU - Australia 16
CZ - Repubblica Ceca 14
BR - Brasile 13
PH - Filippine 13
JP - Giappone 12
IR - Iran 11
MY - Malesia 9
ES - Italia 7
NL - Olanda 7
CH - Svizzera 6
EU - Europa 6
AT - Austria 5
GR - Grecia 5
RO - Romania 5
BZ - Belize 4
KE - Kenya 4
KR - Corea 4
MX - Messico 4
PK - Pakistan 4
ZA - Sudafrica 4
CL - Cile 3
EG - Egitto 3
GP - Guadalupe 3
IL - Israele 3
NG - Nigeria 3
NO - Norvegia 3
PL - Polonia 3
RS - Serbia 3
EC - Ecuador 2
ET - Etiopia 2
LB - Libano 2
PT - Portogallo 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BH - Bahrain 1
CR - Costa Rica 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
JO - Giordania 1
KZ - Kazakistan 1
MA - Marocco 1
MU - Mauritius 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
SV - El Salvador 1
TW - Taiwan 1
UG - Uganda 1
Totale 11.960
Salva come PNG Salva come JPEG
Città #
Southend 1.448
Fairfield 1.059
Woodbridge 702
Ashburn 599
Chandler 497
Houston 489
Seattle 435
Wilmington 385
Cambridge 380
Santa Clara 358
Ann Arbor 327
Jacksonville 313
Dearborn 261
Nyköping 246
Singapore 221
Hong Kong 219
Modena 174
Beijing 157
San Diego 105
New York 92
Princeton 76
Sofia 68
Frankfurt am Main 65
Izmir 63
Eugene 61
Helsinki 55
London 36
Bremen 35
Redwood City 33
Fremont 31
Bologna 29
Milan 29
Brussels 27
Falls Church 27
Jakarta 27
Boardman 24
Shanghai 23
Dublin 21
Rome 21
Dong Ket 20
Nanjing 17
Norwalk 17
Des Moines 16
Toronto 14
San Giuliano Milanese 13
San Jose 12
Guangzhou 11
Phoenix 11
Rho 11
Chicago 10
Kunming 10
Ottawa 10
San Mateo 10
Hefei 9
Parma 9
Trabzon 9
Chengdu 8
Indiana 8
Latina 8
Brno 7
Genoa 7
Hounslow 7
Kilburn 7
Paris 7
Segrate 7
São Paulo 7
Uppsala 7
Melbourne 6
Sydney 6
Bitonto 5
Chiswick 5
Dallas 5
Dongguan 5
Hebei 5
Jinan 5
Los Angeles 5
Prescot 5
Reggio Emilia 5
Verona 5
Wuhan 5
Albuquerque 4
Athens 4
Belize City 4
Cantù 4
Catania 4
Kuala Lumpur 4
Leawood 4
Lille 4
Mirandola 4
Nairobi 4
Nanchang 4
Philadelphia 4
Roncoferraro 4
Saint Petersburg 4
Stoneham 4
Trento 4
Washington 4
Zhengzhou 4
Abano Terme 3
Amritsar 3
Totale 9.652
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 523
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 321
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 293
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 275
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 265
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 259
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 254
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 252
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 251
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 250
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 244
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 243
Activity of BKM120 and BEZ235 against lymphoma cells 241
Empathic attitudes among nursing students: a preliminary study 234
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 233
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 229
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. 222
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 217
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 215
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 208
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 208
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 205
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. 204
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 203
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 197
A concise review of lenalidomide therapy for follicular lymphoma 194
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 191
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 191
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 186
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 184
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 184
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 180
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 179
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 177
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 175
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the fondazione Italiana linfomi 167
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) 165
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 165
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 163
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 161
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 155
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 154
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 153
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 153
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 152
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 151
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 148
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 145
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 145
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 136
Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 135
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 130
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 126
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 123
Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL) 120
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 117
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 109
Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi 108
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 106
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 103
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 100
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 98
Diagnosi di crioproteinemia: preziosa collaborazione tra laboratorio e clinica per la corretta gestione di una patologia rara 82
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 56
Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments (Annals of Hematology, (2020), 99, 2, (277-282), 10.1007/s00277-019-03893-7) 45
Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. A Systematic Review by the Fondazione Italiana Linfomi 38
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 38
The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large b-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi 33
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi 32
Management of multiple myeloma|Terapia del mieloma multiplo 17
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 11
Totale 12.127
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.538
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.538
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.981 0 0 0 0 265 374 379 266 279 129 151 138
2020/20212.396 279 111 184 264 341 140 138 233 118 251 224 113
2021/20221.487 62 110 181 64 28 119 83 112 150 112 266 200
2022/20231.396 152 185 113 141 152 196 25 131 180 13 66 42
2023/20241.099 58 38 75 106 232 72 199 101 33 19 63 103
2024/2025877 104 40 76 245 412 0 0 0 0 0 0 0
Totale 12.127